News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis recruits Anny Bedard as President of Egetis North America

December 20, 2022

Stockholm, Sweden, December 20, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the recruitment of Anny Bedard as President of Egetis North America and as a member of the Company’s leadership team.
Ms. Bedard has over 25 years of international experience in both established and entrepreneurial biopharmaceutical companies, across a broad set of strategic and operating functions in diverse business environments. Her key expertise lies in new market entry, strategic planning, alliance management, country and regional management, product launch, sales and business development.  She has 15 years of experience in the Rare Disease space. Ms. Bedard will be responsible for establishing and maintaining a successful presence of Egetis and its products in the United States and Canada, including establishing the infrastructure for Egetis North America, developing relationships with key national stakeholders, and recruiting a highly effective team to support all initiatives necessary for the successful launch of Emcitate in 2024.
Sara Melton, former President of Egetis North America, will leave the Company to pursue other opportunities.
Nicklas Westerholm, CEO of Egetis, commented:Anny Bedard is a successful industry veteran who has delivered outstanding results across many commercial leadership areas, and I’m delighted to welcome her to Egetis.  During the last 15 years she has focused on devising and executing market entry strategies for rare diseases and establishing new entities, which is a perfect fit with Egetis’ objectives. Anny will be responsible for continuing the establishment of a commercial infrastructure in the US for Emcitate and driving our pre-launch activities ahead of the planned New Drug Application for Emcitate to the FDA in 2023 and launch in 2024. We are also thankful to Sara Melton for her dedicated work to initiate Egetis presence in North America and wish her success in her future endeavors.”
Anny Bedard, President Egetis North America, said: “I am delighted to join Egetis at this important strategic time to establish itself in North America. I admire Egetis for its determination and courage for developing new therapeutics for rare diseases with significant unmet medical needs.  I am inspired by Egetis’ vision and its collaborative culture and look forward to work with this team to build a strong company in North America for the benefit of patients, stakeholders and investors.
Prior to joining Egetis Ms. Bedard served as President of ABio Consulting, where she focused on rare diseases. Anny advised and supported strategic decision making for multiple US and EU biopharma companies across diverse therapeutic areas, technologies and markets to deliver growth at the product, franchise and corporate level.  Before that she was Vice President, Head of International Business, at Sarepta Therapeutics where she designed and executed Sarepta’s entry into Latin America and Asia Pacific. At Shire, she established and led the company’s successful growth in multiple geographies and launched the company’s leading brands in Fabry, Gaucher, Hunter Syndrome and hereditary angioedema.  Ms. Bedard started her career at Fournier Pharma and worked at Serono US before joining Shire and Sarepta. She has a Masters degree in cellular and molecular biology from Laval University in Quebec, Canada.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10